Contraception and menopause hormones compared
Verified · Oct 2026The same two hormones do different jobs: in contraception the progestogen does most of the work and the estrogen controls bleeding; in menopause the estrogen treats the symptoms and the progestogen protects the endometrium. Estrogen carries most of the clot risk in both.
One axis, three timings
Contraception: combined methods suppress the gonadotropins. The progestogen slows GnRH pulses, so FSH and LH fall, no follicle develops and no LH surge occurs; it also makes cervical mucus unfriendly to sperm, while the estrogen controls bleeding. Most progestins used alone also suppress ovulation, but the norethindrone pill does so in only about half of users and also thickens mucus. How the levonorgestrel IUS works locally has not been conclusively demonstrated.
Emergency contraception acts before ovulation. Levonorgestrel blunts the LH surge and inhibits follicular rupture, so it works best before ovulation; it will not work if she is already pregnant. Ulipristal, a selective progesterone receptor modulator, still postpones follicular rupture once LH has started to rise, though not on the day of the LH peak, and it is not indicated to terminate an existing pregnancy. Mifepristone is a competitive antagonist at the progesterone receptor; it is labeled, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation.
Menopause: estrogens reduce the elevated postmenopausal gonadotropins and are thought to act on hot flashes through the hypothalamic neurokinin B pathway. Fezolinetant blocks that pathway directly: it is a neurokinin 3 receptor antagonist in the thermoregulatory center.
Clots follow estrogen — and its route
Elevated estrogen increases the synthesis of coagulation factors, and oral estrogen’s hepatic metabolism adds activated protein C resistance; transdermal estrogen bypasses that hepatic step and has minimal impact on VTE risk. Combined pills raise VTE risk most in the first year and when restarting after a break of 4 weeks or longer, though pregnancy raises it as much or more, and the vaginal ring’s VTE risk is similar to that of pills. Epidemiological studies have not linked progestin-only preparations to MI, stroke or VTE.
For combined methods, category 4 of the CDC’s medical eligibility criteria — basically a contraindication — covers smokers aged 35 or older who smoke 15 or more cigarettes a day, migraine with aura, and the first 21 days postpartum. In menopause therapy, the WHI found more stroke and DVT with estrogen alone, and more stroke, DVT, PE and MI with estrogen plus progestin. A woman with a uterus needs a progestogen because unopposed estrogen raises endometrial cancer risk; after hysterectomy it is unnecessary.
Comparison
Contraception and menopause hormones at a glance
| Method or drug | Main mechanism | Clotting | What steers the choice |
|---|---|---|---|
| Combined pill or ring (norgestimate–EE, Yaz, NuvaRing) | Progestogen slows GnRH pulses → ↓ FSH and LH, no LH surge → no ovulation; unfriendly mucus; estrogen controls bleeding | VTE ↑ — highest in the first year and on restarting after ≥ 4 weeks off; ring similar to pills; stroke and MI with other risk factors | Smoking over 35; DVT or PE now or in the past; inherited or acquired hypercoagulopathy; migraine with aura; uncontrolled hypertension; liver tumors; breast cancer |
| Progestin-only pill (Camila) | Suppresses ovulation in about half of users; thickens mucus; alters the endometrium | Progestin-only preparations not linked to MI, stroke or VTE | Suits many women who cannot take estrogen; typical failure from late or omitted pills — same time every day |
| Etonogestrel implant (Nexplanon) | Suppresses ovulation; more viscous mucus; alters the endometrium | Labeled contraindication: current or past thrombosis | Most effective method; a pregnancy that occurs may be more likely ectopic; pregnancy as early as 7–14 days after removal |
| Medroxyprogesterone injection (Depo-Provera CI) | Inhibits gonadotropins → no follicular maturation or ovulation; thickens mucus | Labeled contraindication: active thrombophlebitis, thromboembolic or cerebrovascular disease | Bone loss — not for longer than 2 years unless other options are inadequate; delayed return of fertility |
| Levonorgestrel IUS (Mirena) | Local: thick mucus, impaired sperm capacitation or survival, endometrial change (not conclusively demonstrated) | — | Uterine perforation; ectopic pregnancy if pregnancy occurs |
| Levonorgestrel EC (Plan B One-Step) | Blunts the LH surge and inhibits follicular rupture; best before ovulation; no significant endometrial effect | — | As soon as possible within 72 hours; over the counter; will not work if already pregnant |
| Ulipristal (ella) | Selective progesterone receptor modulator; postpones follicular rupture even once LH has started to rise | — | Within 120 hours; not with CYP3A4 inducers; start hormonal contraception no sooner than 5 days after |
| Copper IUD (as EC) | Contains no progestin | — | More effective than levonorgestrel methods for EC; increases continued contraceptive use |
| Estrogen alone (after hysterectomy) | Nuclear estrogen receptors; reduces elevated postmenopausal gonadotropins | WHI: stroke and DVT; oral ↑ activated protein C resistance, transdermal minimal VTE impact | Only without a uterus (unopposed estrogen → endometrial cancer); not with DVT, PE, thrombophilia, arterial thromboembolism, or breast cancer outside selected metastatic treatment |
| Estrogen plus progestogen (uterus present) | Progestogen turns proliferative endometrium secretory and reduces hyperplasia | WHI: stroke, DVT, PE and MI | Adds invasive breast cancer risk (WHI); not for preventing cardiovascular disease or dementia; lowest effective dose, shortest duration |
| Fezolinetant (Veozah) | NK3 receptor antagonist: blocks neurokinin B on KNDy neurons in the thermoregulatory center | — | No clear trends in sex hormones; not with CYP1A2 inhibitors, cirrhosis or severe renal impairment |
| Mifepristone | Competitive progesterone-receptor antagonist; sensitizes the myometrium to prostaglandins; blocks the glucocorticoid receptor at high doses | — | Not with chronic adrenal failure, long-term corticosteroids, ectopic pregnancy, bleeding disorders or anticoagulants |
Boxed warnings
| Product | Boxed warning | The reasoning |
|---|---|---|
| Combined pill and ring (norgestimate–EE, NuvaRing) | Cigarette smoking and serious cardiovascular events | The risk rises with age, particularly over 35, and with the number of cigarettes; not used by women over 35 who smoke |
| Medroxyprogesterone injection (Depo-Provera CI) | Loss of bone mineral density | It lowers serum estrogen; the loss grows with duration and may not be completely reversible |
| Etonogestrel implant (Nexplanon) | Complications due to improper insertion and removal | Improper insertion increases the risk of complications |
| Conjugated estrogens (Premarin) | Endometrial cancer, cardiovascular disorders, breast cancer and probable dementia | Unopposed estrogen raises endometrial cancer risk with a uterus; WHI stroke and DVT; probable dementia at 65 and older |
| Medroxyprogesterone tablets (Provera) | Cardiovascular disorders, breast cancer and probable dementia for estrogen plus progestin therapy | WHI: stroke, DVT, PE, MI and invasive breast cancer |
| Mifepristone | Serious and sometimes fatal infections and bleeding | They occur very rarely; available only through a REMS because of the risk of serious complications |
| Fezolinetant (Veozah) | Hepatotoxicity | Hepatic tests before starting and during treatment; stop at once for signs of liver injury |
High-yield
Practice questions
Q1A 38-year-old woman who smokes 20 cigarettes a day wants a reversible contraceptive. She has no other medical problems.
Which method is most appropriate?
- A.Norgestimate–ethinyl estradiol pill
- B.Etonogestrel–ethinyl estradiol vaginal ring, because vaginal estrogen avoids the clot risk of pills
- C.Medroxyprogesterone injection, because it carries no boxed warning
- D.Etonogestrel implant
Show answer
D. Etonogestrel implant — Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptives, particularly over 35, so combined methods — including the ring — should not be used by women over 35 who smoke; the ring’s VTE risk is similar to that of pills. The medroxyprogesterone injection carries a boxed warning for loss of bone mineral density. Epidemiological studies have not linked progestin-only preparations to MI, stroke or VTE, and the implant is among the most effective methods.
Q2A 30-year-old woman had unprotected intercourse 2 days ago. She wants emergency contraception and then a long-term method, and she prefers to avoid hormones.
Which option best fits?
- A.Copper IUD
- B.Levonorgestrel tablet
- C.Ulipristal tablet
- D.Combined oral contraceptive pill
Show answer
A. Copper IUD — The copper IUD is a postcoital option that does not involve progestins; a meta-analysis found it more effective than levonorgestrel-containing methods for emergency contraception, and it increases continued contraceptive use. Levonorgestrel is a progestin that binds progesterone and androgen receptors, ulipristal is a selective progesterone receptor modulator, and a combined pill contains both a progestin and an estrogen.
Q3A 55-year-old woman with an intact uterus has moderate to severe hot flashes due to menopause. She asks for a treatment that is not a hormone.
Which drug fits her request?
- A.Oral estradiol with a progestogen
- B.Fezolinetant
- C.Medroxyprogesterone tablets alone
- D.Conjugated estrogens with bazedoxifene
Show answer
B. Fezolinetant — Fezolinetant, a neurokinin 3 receptor antagonist, blocks neurokinin B signaling on KNDy neurons in the thermoregulatory center and is indicated for moderate to severe vasomotor symptoms due to menopause; it showed no clear trends in sex hormones. Oral estradiol acts on nuclear estrogen receptors, and a woman with a uterus takes it with a progestogen because unopposed estrogen raises endometrial cancer risk. Medroxyprogesterone is itself a progestin, added to estrogen to reduce endometrial hyperplasia. Conjugated estrogens with bazedoxifene pairs estrogens with an agent that is an agonist in some estrogen-sensitive tissues and an antagonist in the uterus.
Q4A 23-year-old woman restarts her combined oral contraceptive after stopping it for 6 weeks. She asks about blood clots.
Which statement is correct?
- A.Pregnancy carries a lower VTE risk than her pill
- B.Switching to the vaginal ring would remove the estrogen-related clot risk
- C.The progestin, not the estrogen, raises the synthesis of clotting factors
- D.Her VTE risk is highest in the first year of use and when restarting after a break of 4 weeks or longer
Show answer
D. Her VTE risk is highest in the first year of use and when restarting after a break of 4 weeks or longer — The risk of VTE is highest during the first year of combined-pill use and when restarting after a break of 4 weeks or longer. Pregnancy increases VTE risk as much as or more than the pill does, and ring users have a VTE risk similar to pill users. Elevated estrogen levels mediate the increased synthesis of coagulation factors.
Sources
- Norgestimate and ethinyl estradiol tablets (Glenmark) — FDA label — FDA / DailyMed
- Oral Contraceptive Pills — StatPearls (NCBI)
- Yaz (drospirenone/ethinyl estradiol) — FDA label — FDA / DailyMed
- Slynd (drospirenone) — FDA label — FDA / DailyMed
- Camila (norethindrone) — FDA label — FDA / DailyMed
- Mirena (levonorgestrel IUS) — FDA label — FDA / DailyMed
- Plan B One-Step (levonorgestrel) — FDA label — FDA / DailyMed
- U.S. Medical Eligibility Criteria for Contraceptive Use (2024) — combined hormonal contraceptives — CDC
- Physiology, Maternal Changes — StatPearls (NCBI)
- Hormone Replacement Therapy — StatPearls (NCBI)
- Nexplanon (etonogestrel implant) — FDA label — FDA / DailyMed
- NuvaRing (etonogestrel/ethinyl estradiol ring) — FDA label — FDA / DailyMed
- Depo-Provera CI (medroxyprogesterone acetate) — FDA label — FDA / DailyMed
- ella (ulipristal acetate) — FDA label — FDA / DailyMed
- Contraception — StatPearls (NCBI)
- Progestins — StatPearls (NCBI)
- Levonorgestrel — StatPearls (NCBI)
- Mifepristone — StatPearls (NCBI)
- Physiology, Menstrual Cycle — StatPearls (NCBI)
- Climara (estradiol transdermal system) — FDA label — FDA / DailyMed
- Estring (estradiol vaginal system) — FDA label — FDA / DailyMed
- Premarin (conjugated estrogens) tablets — FDA label — FDA / DailyMed
- Premarin Vaginal (conjugated estrogens) cream — FDA label — FDA / DailyMed
- Duavee (conjugated estrogens/bazedoxifene) — FDA label — FDA / DailyMed
- Prometrium (progesterone) capsules — FDA label — FDA / DailyMed
- Crinone (progesterone gel) — FDA label — FDA / DailyMed
- Provera (medroxyprogesterone acetate) tablets — FDA label — FDA / DailyMed
- Mifepristone tablets (GenBioPro) — FDA label — FDA / DailyMed
- Veozah (fezolinetant) — FDA label — FDA / DailyMed
Each class page compared lists its full sources; this page reuses facts verified there.
By LearnDrugs
Educational summary for medical students. Always verify against current prescribing information and guidelines. Not medical advice.